Top

Neurology and Therapy

Published in:

Open Access 14-09-2023 | Diroximel Fumarate | LETTER

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

Authors: Pelayo Nieto-Gómez, Celia Castaño-Amores

Published in: Neurology and Therapy | Issue 6/2023

Excerpt

Dear Editor …

Lager B, Liseno J, Božin I, et al. Real-World analysis affirms the high persistence and adherence observed with diroximel fumarate in patients with multiple sclerosis. Neurol Ther. 2023;12:145–59. https://doi.org/10.1007/s40120-022-00413-0.CrossRefPubMed

Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36(11):3154–65. https://doi.org/10.1007/s12325-019-01085-3.CrossRefPubMedPubMedCentral

Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, doubleblind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185–96. https://doi.org/10.1007/s40263-020-00700-0.CrossRefPubMedPubMedCentral

European Medicines Agency. European public assessment report of vumerity. https://www.ema.europa.eu/en/medicines/human/EPAR/vumerity. Accessed 15 June 2023

Araujo L, Geertsen SS, Amedume A, Higuchi K, van Wingerden J. Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study. Neurol Ther. 2022;11(4):1735–48. https://doi.org/10.1007/s40120-022-00404-1.CrossRefPubMedPubMedCentral

Thompson MT, Virginia D, Nick B, Melissa G, Engineer N, Shen C, Reedie S. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): long-term Canadian experience from the Biogen ONE™ support program. Mult Scler Relat Disord. 2022;67:104080. https://doi.org/10.1016/j.msard.2022.104080.CrossRefPubMed

Title: Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
Authors: Pelayo Nieto-Gómez
Celia Castaño-Amores
Publication date: 14-09-2023
Publisher: Springer Healthcare
Keywords: Diroximel Fumarate
Dimethyl Fumarate
Multiple Sclerosis
Published in: Neurology and Therapy / Issue 6/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-023-00537-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2023

Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE

Evaluating Perceived Fatigue within an Adult Spinal Muscular Atrophy Population

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial